Showing 221-230 of 290 results for "".
- Research Closes in on the Genetic Factors Underlying HS Riskhttps://practicaldermatology.com/news/research-closes-in-on-the-genetic-factors-underlying-hs-risk/2461893/Researchers have identified genetic locations for increased risk of hidradenitis suppurativa (HS). “This discovery is highly relevant because these changes may effect nearby genes in a way that leads to improper development of hair follicles and predispose them to the rupture,&rdq
- Hoth Therapeutics Receives Protocol Approval for HT-001https://practicaldermatology.com/news/hoth-therapeutics-receives-protocol-approval-for-ht-001/2461873/Hoth Therapeutics, Inc. received approval from the Food & Drug Administration (FDA) for a protocol change in its Phase 2a clinical trial of HT-001. Participants will apply HT-001 Gel once per day for six weeks, during which the effect on treating acneiform rash and other skin
- AD Pipeline Watch: Eblasakimab Monthly Dosing Shows Promise in Phase 2b AD Studyhttps://practicaldermatology.com/news/eblasakimab-monthly-dosing-shows-promise-in-phase-2b-ad-study/2461845/ASLAN Pharmaceuticals’ eblasakimab met the primary endpoint of percent change from baseline in the Eczema Area and Severity Index (EASI) score at week 16 versus placebo in adult patients with moderate-to-severe atopic dermatitis (AD), according to results from the Phase 2b dose-ra
- Researchers Uncover Clues Driving PsO Spread and Severityhttps://practicaldermatology.com/news/researchers-uncover-clues-driving-pso-spread-and-severity/2461759/New research sheds light on the cellular changes that drive psoriasis severity and also offers important clues about how the disease spreads to other parts of the body. Specifically, the location of clusters of fibroblasts and macrophages tend to occur more commonly in the upper l
- First Patient Dosed in TrialSpark's Phase 2 Trial of ASN008-201 in ADhttps://practicaldermatology.com/news/first-patient-dosed-in-trailsparks-phase-2-trial-of-asn008-201-in-ad/2461736/The first patient has been dosed in TrialSpark’s Phase 2 clinical trial for ASN008-201, a topical sodium channel blocker in development for pruritus associated with atopic dermatitis (AD). This clinical trial is a randomized, double-blind, vehicle-controlled, Phase 2 tr
- LEO Pharma Adds to Global Leadership Teamhttps://practicaldermatology.com/news/leo-pharma-adds-to-global-leadership-team/2461607/Dr. Jacob Pontoppidan Thyssen is the new Executive Vice President and Chief Scientific Officer for LEO Pharma’s Research and Early Development arm. The company announced that a significant shift in R&D to a research model in early 2023. The change aims to drive the early-stage
- Long-term, Systemic Antibiotic Use for Teen Acne May Promote Fat Accumulationhttps://practicaldermatology.com/news/long-term-systemic-antibiotic-use-for-teen-acne-may-promote-fat-accumulation/2461603/Long-term antibiotic use for the treatment of adolescent acne disrupts the healthy gut microbiome, leading to changes in liver metabolism that promotes the accumulation of central fat, a new study shows. Around 25 percent of adolescents require systemic antibiotics, such as minocycline,
- Relief Therapeutics Enrolls First Patients in Proof-of-Concept Trial of Epidermolysis Bullosa Treatmenthttps://practicaldermatology.com/news/relief-therapeutics-enrolls-first-patients-in-proof-of-concept-trial-of-epidermolysis-bullosa-treatment/2461563/Relief Therapeutics announced the first three patients have been enrolled in a proof-of-concept, investigator-initiated study to evaluate RLF-TD011 as a treatment for epidermolysis bullosa (EB). The primary aim of the study will be to assess changes in the skin microbiome (Staphylococcu
- Researchers Identify Protein that Helps Melanoma Spread Throughout the Bodyhttps://practicaldermatology.com/news/researchers-identify-protein-that-helps-melanoma-spread-throughout-the-body/2461495/Research led by Queen Mary University of London, King’s College London and the Francis Crick Institute has identified a protein that makes melanoma more aggressive by giving cancer cells the ability to change the shape of their nucleus–a characteristic which allows the cells to migrat
- Zubin Meshginpoosh Named President and COO at Sentéhttps://practicaldermatology.com/news/zubin-meshginpoosh-named-president-and-coo-at-sente/2461463/Zubin Meshginpoosh is now the President and Chief Operational Officer of Senté. "Zubin has an incredible track record for enabling teams to achieve success in high growth and fast-changing environments," says Faheem Hasnain, Chairman of the Board at Senté, in a n